DK2914248T4 - Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme - Google Patents

Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme Download PDF

Info

Publication number: DK2914248T4
Authority: DK; Denmark
Prior art keywords: treatment; pharmaceutical compositions; mediated diseases; cftr mediated; cftr
Prior art date: 2012-11-02

Application number

DK13792149.0T

Other languages

English (en)

Other versions

DK2914248T3 (da

Inventor

Marinus Jacobus Verwijs

Radhika Karkare

Michael Douglas Moore

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-02

Filing date

2013-11-01

Publication date

2024-01-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2914248(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-11-01 Application filed by Vertex Pharma filed Critical Vertex Pharma

2018-11-26 Publication of DK2914248T3 publication Critical patent/DK2914248T3/da

2024-01-02 Application granted granted Critical

2024-01-02 Publication of DK2914248T4 publication Critical patent/DK2914248T4/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Dispersion Chemistry (AREA)
Biophysics (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK13792149.0T 2012-11-02 2013-11-01 Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme DK2914248T4 (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201261721622P	2012-11-02	2012-11-02
US201261728328P	2012-11-20	2012-11-20
US201361770668P	2013-02-28	2013-02-28
US201361824005P	2013-05-16	2013-05-16
US201361840668P	2013-06-28	2013-06-28
PCT/US2013/067952 WO2014071122A1 (en)	2012-11-02	2013-11-01	Pharmaceutical compositions for the treatment of cftr mediated diseases

Publications (2)

Publication Number	Publication Date
DK2914248T3 DK2914248T3 (da)	2018-11-26
DK2914248T4 true DK2914248T4 (da)	2024-01-02

Family

ID=50628072

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK13792149.0T DK2914248T4 (da)	2012-11-02	2013-11-01	Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme
DK18192504.1T DK3470063T3 (da)	2012-11-02	2013-11-01	Farmaceutiske sammensætninger til behandling af cftr-medierede sygdomme

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK18192504.1T DK3470063T3 (da)	2012-11-02	2013-11-01	Farmaceutiske sammensætninger til behandling af cftr-medierede sygdomme

Country Status (31)

Country	Link
US (4)	US20140163068A1 (da)
EP (2)	EP2914248B2 (da)
JP (4)	JP6302923B2 (da)
KR (1)	KR102396897B1 (da)
CN (2)	CN111671751A (da)
AR (1)	AR093340A1 (da)
AU (4)	AU2013337730B2 (da)
BR (1)	BR112015009913B1 (da)
CA (1)	CA2890106C (da)
CL (1)	CL2015001148A1 (da)
CY (1)	CY1121070T1 (da)
DK (2)	DK2914248T4 (da)
ES (1)	ES2694290T5 (da)
FI (1)	FI2914248T4 (da)
HK (1)	HK1212632A1 (da)
HR (1)	HRP20181740T4 (da)
HU (1)	HUE039864T2 (da)
IL (2)	IL283276B2 (da)
LT (2)	LT3470063T (da)
MX (2)	MX368353B (da)
NZ (2)	NZ745659A (da)
PL (1)	PL2914248T5 (da)
PT (1)	PT2914248T (da)
RS (1)	RS57831B2 (da)
SG (3)	SG10201703452PA (da)
SI (1)	SI2914248T2 (da)
SM (1)	SMT201800590T1 (da)
TR (1)	TR201815218T4 (da)
TW (2)	TW201422253A (da)
UA (2)	UA117464C2 (da)
WO (1)	WO2014071122A1 (da)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
EP1664006A2 (en)	2003-09-06	2006-06-07	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
PT2489659T (pt)	2004-06-24	2018-03-07	Vertex Pharma	Moduladores de transportadores de cassete de ligação a atp
KR20080053297A (ko)	2005-08-11	2008-06-12	버텍스 파마슈티칼스 인코포레이티드	낭포성 섬유종 트랜스막 전도도 조정자의 조절자
EP1945632B1 (en)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of atp-binding cassette transporters
SI3219705T1 (sl)	2005-12-28	2020-08-31	Vertex Pharmaceuticals Incorporated	Farmacevtski sestavki amorfne oblike N-(2,4-bis(1,1-dimetiletil)-5- hidroksifenil)-1,4-dihidro-4-oksokinolin-3-karboksamid
SI3091011T1 (en)	2006-04-07	2018-06-29	Vertex Pharmaceuticals Incorporated	Modulators of ATP conveyor belt conveyors
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
CA2686838C (en)	2007-05-09	2017-03-14	Vertex Pharmaceuticals Incorporated	Modulators of cftr
ES2578735T3 (es)	2007-08-24	2016-07-29	Vertex Pharmaceuticals Incorporated	Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística
NZ598941A (en)	2007-11-16	2013-06-28	Vertex Pharma	Isoquinoline modulators of ATP-Binding Cassette transporters
ES2625957T3 (es)	2007-12-07	2017-07-21	Vertex Pharmaceuticals Incorporated	Procedimiento para producir ácidos cicloalquilcarboxiamido-piridinabenzoicos
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
RS60229B1 (sr)	2007-12-07	2020-06-30	Vertex Pharma	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il) benzojeve kiseline
CA2716109C (en)	2008-02-28	2016-07-19	Vertex Pharmaceuticals Incorporated	Heteroaryl derivatives as cftr modulators
SG193156A1 (en)	2009-03-20	2013-09-30	Vertex Pharma	Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
DK3150198T3 (da)	2010-04-07	2021-11-01	Vertex Pharma	Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
AR081069A1 (es)	2010-04-07	2012-06-06	Vertex Pharma	Formas solidas del acido 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico
US9035072B2 (en)	2010-04-22	2015-05-19	Vertex Pharmaceuticals Incorporated	Process of producing cycloalkylcarboxamido-indole compounds
HUE047354T2 (hu)	2011-05-18	2020-04-28	Vertex Pharmaceuticals Europe Ltd	Ivacaftor deuterizált származékai
CA2852991C (en)	2011-11-08	2019-12-31	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
JP2015508407A (ja)	2012-01-06	2015-03-19	アビデセラピューティクス，インク．	カルバメート化合物およびその製造および使用
CN109966264A (zh)	2012-02-27	2019-07-05	沃泰克斯药物股份有限公司	药物组合物及其施用
EP2872122A1 (en)	2012-07-16	2015-05-20	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
TW201422253A (zh) *	2012-11-02	2014-06-16	Vertex Pharma	治療ｃｆｔｒ介導疾病之醫藥組合物
US9303918B2 (en) *	2013-03-15	2016-04-05	Monosol Rx, Llc	Process for drying a wet film with control of loss on drying
WO2014176553A1 (en) *	2013-04-26	2014-10-30	Vertex Pharmaceuticals Incorporated	Correctors acting through msd1 of cftr protein
MX2016006118A (es)	2013-11-12	2016-07-21	Vertex Pharma	Proceso para preparar composiciones farmaceuticas para el tratamiento de enfermedades mediadas por regulador de la conductancia transmembrana de la fibrosis quistica (cftr).
PT3925607T (pt)	2014-04-15	2023-09-26	Vertex Pharma	Composições farmacêuticas para o tratamento de doenças mediadas pelo regulador de condutância transmembranar da fibrose quística
US9782408B2 (en)	2014-10-06	2017-10-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
ES2702288T3 (es)	2014-10-07	2019-02-28	Vertex Pharma	Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
BR112017010406B1 (pt)	2014-11-18	2021-03-09	Vertex Pharmaceuticals Incorporated	processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência
JP2018515460A (ja)	2015-05-11	2018-06-14	アビデセラピューティクス，インク．	炎症または神経障害性疼痛を処置する方法
US10759721B2 (en)	2015-09-25	2020-09-01	Vertex Pharmaceuticals (Europe) Limited	Deuterated CFTR potentiators
WO2017151725A1 (en) *	2016-03-03	2017-09-08	Nivalis Therapeutics, Inc.	Formulations of an s-nitrosoglutathione reductase inhibitor
ES2946970T3 (es)	2016-03-31	2023-07-28	Vertex Pharma	Regulador de conductancia transmembrana de moduladores de fibrosis quística
HUP1600270A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
US10206915B2 (en)	2016-04-25	2019-02-19	Druggability Technologies Ip Holdco Limited	Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600271A2 (hu) *	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
US10376501B2 (en)	2016-04-25	2019-08-13	Druggability Technologies Ip Holdco Limited	Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600269A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
US10383865B2 (en)	2016-04-25	2019-08-20	Druggability Technologies Ip Holdco Limited	Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
JOP20190042B1 (ar)	2016-09-30	2021-08-17	Vertex Pharma	مُعدِّل‏ لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل
KR20190085046A (ko)	2016-11-16	2019-07-17	어바이드 테라퓨틱스, 인크.	약학 제제
HUE064559T2 (hu)	2016-11-16	2024-03-28	H Lundbeck As	MAGL inhibitor kristályos formája
PE20241131A1 (es)	2016-12-09	2024-05-24	Vertex Pharma	Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador
AU2018279646B2 (en)	2017-06-08	2023-04-06	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
WO2019018395A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	METHODS OF TREATING CYSTIC FIBROSIS
EP3661915B1 (en)	2017-08-02	2022-03-09	Vertex Pharmaceuticals Incorporated	Processes for preparing pyrrolidine compounds
MA50400A (fr)	2017-10-19	2020-08-26	Vertex Pharma	Formes cristallines et compositions de modulateurs de cftr
CA3082444A1 (en)	2017-12-01	2019-06-06	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
NZ765171A (en)	2017-12-08	2024-12-20	Vertex Pharma	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
IL294042A (en)	2018-02-15	2022-08-01	Vertex Pharma	Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
WO2019195739A1 (en)	2018-04-05	2019-10-10	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator
WO2019200246A1 (en)	2018-04-13	2019-10-17	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
LT3880197T (lt)	2018-11-14	2023-05-10	Vertex Pharmaceuticals Incorporated	Cistinės fibrozės gydymo būdai
TWI848092B (zh)	2019-04-03	2024-07-11	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白調節劑
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
KR20220064366A (ko)	2019-08-14	2022-05-18	버텍스 파마슈티칼스 인코포레이티드	Cftr 조절제의 결정질 형태
JP2022545359A (ja)	2019-08-14	2022-10-27	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子モジュレーター
US11591350B2 (en)	2019-08-14	2023-02-28	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
TW202120517A (zh)	2019-08-14	2021-06-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
US11904006B2 (en)	2019-12-11	2024-02-20	University Of Iowa Research Foundation	Poly(diaminosulfide) particle-based vaccine
IL297470A (en)	2020-04-21	2022-12-01	H Lundbeck As	Synthesis of a monoacylglycerol lipase inhibitor
WO2022194399A1 (en)	2020-07-13	2022-09-22	Idorsia Pharmaceuticals Ltd	Macrocycles as cftr modulators
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US20230382924A1 (en)	2020-10-07	2023-11-30	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373935A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
JP2023545762A (ja)	2020-10-07	2023-10-31	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子
US20230365587A1 (en)	2020-10-07	2023-11-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076628A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
IL301755A (en)	2020-10-07	2023-05-01	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225761A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373974A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
MX2023004072A (es)	2020-10-07	2023-07-05	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
WO2022076626A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CA3204725A1 (en)	2020-12-10	2022-06-16	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
US20240100183A1 (en) *	2020-12-11	2024-03-28	University Of Iowa Research Foundation	Compositions comprising molecules for cystic fibrosis treatment
TW202333699A (zh)	2022-02-03	2023-09-01	美商維泰克斯製藥公司	囊腫纖維化之治療方法
CN118974059A (zh)	2022-02-08	2024-11-15	弗特克斯药品有限公司	囊性纤维化跨膜传导调控因子的调节剂
AU2023249173A1 (en)	2022-04-06	2024-10-03	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224931A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
TW202421102A (zh)	2022-09-15	2024-06-01	瑞士商愛杜西亞製藥有限公司	巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合
WO2024056798A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators
WO2024056779A1 (en)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020017295A1 (en)	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
BR0314943A (pt)	2002-09-30	2005-08-02	Univ California	Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
WO2004080972A1 (en)	2003-03-12	2004-09-23	Vertex Pharmaceuticals Incorporated	Pirazole modulators of atp-binding cassette transporters
PL3345895T3 (pl)	2003-04-11	2020-05-18	Ptc Therapeutics, Inc.	Związek kwasu 1,2,4-oksadiazolobenzoesowego i jego zastosowanie do supresji mutacji nonsensownych i leczenia choroby
US7696244B2 (en)	2003-05-16	2010-04-13	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
EP1646615B1 (en)	2003-06-06	2009-08-26	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
CA2465565A1 (en) *	2003-06-12	2004-12-12	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
KR20060121909A (ko)	2003-10-08	2006-11-29	버텍스 파마슈티칼스 인코포레이티드	사이클로알킬 또는 피라닐 그룹을 포함하는 ａｔｐ-결합카세트 수송자의 조절자
WO2005049018A1 (en)	2003-11-14	2005-06-02	Vertex Pharmaceuticals Incorporated	Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
CA2561560A1 (en)	2004-03-30	2005-10-13	The Regents Of The University Of California	Hydrazide-containing cftr inhibitor compounds and uses thereof
US7939558B2 (en)	2004-06-04	2011-05-10	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
PT2489659T (pt)	2004-06-24	2018-03-07	Vertex Pharma	Moduladores de transportadores de cassete de ligação a atp
US7902235B2 (en)	2004-10-13	2011-03-08	Ptc Therapeutics, Inc.	Compounds for nonsense suppression, and methods for their use
WO2006099256A2 (en)	2005-03-11	2006-09-21	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
RU2007138584A (ru)	2005-03-18	2009-04-27	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния (Us)	Соединения, обладающие активностью для коррекции процессинга мутантного cftr, и их применение
DK1874306T3 (da)	2005-04-08	2012-10-01	Ptc Therapeutics Inc	Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi
WO2006127588A2 (en)	2005-05-24	2006-11-30	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
EP1933831A2 (en)	2005-10-06	2008-06-25	Vertex Pharmaceuticals, Inc.	Modulators of atp-binding cassette transporters
EP1945632B1 (en)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of atp-binding cassette transporters
ATE499363T1 (de)	2007-05-07	2011-03-15	Novartis Ag	Organische verbindungen
NZ620027A (en) *	2007-09-14	2015-05-29	Vertex Pharma	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
RS60229B1 (sr)	2007-12-07	2020-06-30	Vertex Pharma	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il) benzojeve kiseline
WO2009074575A2 (en)	2007-12-10	2009-06-18	Novartis Ag	Organic compounds
BRPI0915018A2 (pt)	2008-06-10	2015-10-27	Novartis Ag	compostos orgânicos
KR20110042356A (ko)	2008-08-13	2011-04-26	버텍스 파마슈티칼스 인코포레이티드	제약 조성물 및 그의 투여
US8716338B2 (en) *	2008-09-29	2014-05-06	Vertex Pharmaceuticals Incorporated	Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NZ596868A (en) *	2009-06-02	2014-04-30	Nikan Pharmaceuticals Llc	Antagonism of human formyl peptide receptor for treatment of disease
JP2011034380A (ja) *	2009-08-03	2011-02-17	Nitto Denko Corp	タッチパネルおよびタッチパネル付表示装置
WO2011028740A1 (en)	2009-09-03	2011-03-10	Glaxo Group Limited	ENaC BLOCKERS
WO2011079087A1 (en)	2009-12-23	2011-06-30	Glaxo Group Limited	Enac blockers
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
DK3150198T3 (da) *	2010-04-07	2021-11-01	Vertex Pharma	Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf
NZ603042A (en) *	2010-04-22	2015-02-27	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
US8372845B2 (en)	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
US10105356B2 (en) *	2011-01-31	2018-10-23	Avalyn Pharma Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9968607B2 (en)	2011-04-25	2018-05-15	Hetero Research Foundation	Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
RU2644723C2 (ru) *	2012-01-25	2018-02-13	Вертекс Фармасьютикалз Инкорпорейтед	Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
TW201422253A (zh) *	2012-11-02	2014-06-16	Vertex Pharma	治療ｃｆｔｒ介導疾病之醫藥組合物

2013
- 2013-11-01 TW TW102139864A patent/TW201422253A/zh unknown
- 2013-11-01 RS RS20181318A patent/RS57831B2/sr unknown
- 2013-11-01 FI FIEP13792149.0T patent/FI2914248T4/fi active
- 2013-11-01 NZ NZ745659A patent/NZ745659A/en unknown
- 2013-11-01 ES ES13792149T patent/ES2694290T5/es active Active
- 2013-11-01 SG SG10201703452PA patent/SG10201703452PA/en unknown
- 2013-11-01 TW TW107117580A patent/TWI736768B/zh active
- 2013-11-01 PT PT13792149T patent/PT2914248T/pt unknown
- 2013-11-01 HU HUE13792149A patent/HUE039864T2/hu unknown
- 2013-11-01 MX MX2015005559A patent/MX368353B/es active IP Right Grant
- 2013-11-01 UA UAA201505319A patent/UA117464C2/uk unknown
- 2013-11-01 SG SG10201913581UA patent/SG10201913581UA/en unknown
- 2013-11-01 EP EP13792149.0A patent/EP2914248B2/en active Active
- 2013-11-01 CA CA2890106A patent/CA2890106C/en active Active
- 2013-11-01 SM SM20180590T patent/SMT201800590T1/it unknown
- 2013-11-01 TR TR2018/15218T patent/TR201815218T4/tr unknown
- 2013-11-01 DK DK13792149.0T patent/DK2914248T4/da active
- 2013-11-01 LT LTEP18192504.1T patent/LT3470063T/lt unknown
- 2013-11-01 HR HRP20181740TT patent/HRP20181740T4/hr unknown
- 2013-11-01 IL IL283276A patent/IL283276B2/en unknown
- 2013-11-01 SG SG11201503365YA patent/SG11201503365YA/en unknown
- 2013-11-01 UA UAA201803746A patent/UA123631C2/uk unknown
- 2013-11-01 WO PCT/US2013/067952 patent/WO2014071122A1/en active Application Filing
- 2013-11-01 AU AU2013337730A patent/AU2013337730B2/en active Active
- 2013-11-01 BR BR112015009913-0A patent/BR112015009913B1/pt active IP Right Grant
- 2013-11-01 SI SI201331163T patent/SI2914248T2/sl unknown
- 2013-11-01 PL PL13792149.0T patent/PL2914248T5/pl unknown
- 2013-11-01 LT LTEP13792149.0T patent/LT2914248T/lt unknown
- 2013-11-01 JP JP2015540796A patent/JP6302923B2/ja active Active
- 2013-11-01 KR KR1020157014464A patent/KR102396897B1/ko active IP Right Grant
- 2013-11-01 US US14/069,571 patent/US20140163068A1/en not_active Abandoned
- 2013-11-01 CN CN202010527346.2A patent/CN111671751A/zh active Pending
- 2013-11-01 NZ NZ708474A patent/NZ708474A/en unknown
- 2013-11-01 EP EP18192504.1A patent/EP3470063B1/en active Active
- 2013-11-01 CN CN201380066317.9A patent/CN104869982A/zh active Pending
- 2013-11-01 DK DK18192504.1T patent/DK3470063T3/da active
- 2013-11-04 AR ARP130104018A patent/AR093340A1/es not_active Application Discontinuation
2015
- 2015-04-30 MX MX2019011662A patent/MX2019011662A/es unknown
- 2015-04-30 IL IL238551A patent/IL238551B/en active IP Right Grant
- 2015-04-30 CL CL2015001148A patent/CL2015001148A1/es unknown
2016
- 2016-01-22 HK HK16100724.5A patent/HK1212632A1/zh active IP Right Maintenance
- 2016-05-11 US US15/152,092 patent/US20160324846A1/en not_active Abandoned
2018
- 2018-03-05 JP JP2018038741A patent/JP2018090626A/ja not_active Withdrawn
- 2018-09-14 AU AU2018229528A patent/AU2018229528A1/en not_active Abandoned
- 2018-11-30 CY CY20181101277T patent/CY1121070T1/el unknown
2019
- 2019-05-07 JP JP2019087813A patent/JP7003085B2/ja active Active
- 2019-12-20 US US16/722,290 patent/US20200338063A1/en not_active Abandoned
2020
- 2020-06-17 AU AU2020204037A patent/AU2020204037B2/en active Active
2021
- 2021-12-28 JP JP2021214209A patent/JP2022034069A/ja active Pending
2022
- 2022-12-30 US US18/091,472 patent/US20230364073A1/en active Pending
2024
- 2024-01-16 AU AU2024200273A patent/AU2024200273A1/en active Pending

Also Published As

Publication number	Publication date
JP2018090626A (ja)	2018-06-14
IL283276A (en)	2021-07-29
RS57831B1 (sr)	2018-12-31
RU2015120798A (ru)	2016-12-27
EP2914248B2 (en)	2023-10-18
CN104869982A (zh)	2015-08-26
NZ708474A (en)	2019-02-22
AU2020204037B2 (en)	2023-10-19
RS57831B2 (sr)	2024-02-29
SG10201913581UA (en)	2020-02-27
RU2692676C2 (ru)	2019-06-26
SI2914248T2 (sl)	2023-12-29
UA117464C2 (uk)	2018-08-10
AU2018229528A1 (en)	2018-10-11
IL238551A0 (en)	2015-06-30
PL2914248T3 (pl)	2019-01-31
AR093340A1 (es)	2015-06-03
MX2015005559A (es)	2015-10-29
EP2914248A1 (en)	2015-09-09
JP6302923B2 (ja)	2018-03-28
IL238551B (en)	2021-06-30
KR102396897B1 (ko)	2022-05-13
BR112015009913B1 (pt)	2023-04-11
AU2013337730B2 (en)	2018-06-14
ES2694290T3 (es)	2018-12-19
HK1212632A1 (zh)	2016-06-17
DK2914248T3 (da)	2018-11-26
IL283276B2 (en)	2024-05-01
LT2914248T (lt)	2018-11-26
CA2890106A1 (en)	2014-05-08
SMT201800590T1 (it)	2019-01-11
TR201815218T4 (tr)	2018-11-21
HRP20181740T1 (hr)	2018-12-28
SG11201503365YA (en)	2015-06-29
HUE039864T2 (hu)	2019-02-28
ES2694290T5 (es)	2024-05-21
US20160324846A1 (en)	2016-11-10
DK3470063T3 (da)	2025-01-20
FI2914248T4 (fi)	2023-12-19
TW201842907A (zh)	2018-12-16
LT3470063T (lt)	2025-02-10
US20140163068A1 (en)	2014-06-12
WO2014071122A1 (en)	2014-05-08
IL283276B1 (en)	2024-01-01
KR20150080609A (ko)	2015-07-09
BR112015009913A8 (pt)	2019-09-17
JP2022034069A (ja)	2022-03-02
AU2020204037A1 (en)	2020-07-09
SI2914248T1 (sl)	2018-12-31
PT2914248T (pt)	2018-11-29
NZ745659A (en)	2020-04-24
US20200338063A1 (en)	2020-10-29
MX2019011662A (es)	2019-11-18
AU2024200273A1 (en)	2024-02-01
CA2890106C (en)	2022-08-02
RU2019117882A (ru)	2019-10-04
TW201422253A (zh)	2014-06-16
CY1121070T1 (el)	2020-05-29
JP7003085B2 (ja)	2022-02-04
AU2013337730A1 (en)	2015-06-11
PL2914248T5 (pl)	2024-01-15
US20230364073A1 (en)	2023-11-16
CL2015001148A1 (es)	2016-02-19
BR112015009913A2 (pt)	2017-07-11
MX368353B (es)	2019-09-30
SG10201703452PA (en)	2017-06-29
TWI736768B (zh)	2021-08-21
CN111671751A (zh)	2020-09-18
EP3470063A1 (en)	2019-04-17
EP2914248B1 (en)	2018-09-05
JP2015535289A (ja)	2015-12-10
UA123631C2 (uk)	2021-05-05
EP3470063B1 (en)	2025-01-01
HRP20181740T4 (hr)	2024-01-05
JP2019142956A (ja)	2019-08-29

Publication	Publication Date	Title
DK2914248T4 (da)	2024-01-02	Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme
HRP20210516T1 (hr)	2021-05-14	Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
DK2818482T3 (da)	2019-07-15	Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da)	2019-07-29	Farmaceutisk sammensætning til behandling af cancer
DK2919796T3 (da)	2021-05-31	Brug af akkermansia til behandling af stofskiftesygdomme
DK2895156T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK3520805T3 (da)	2021-04-19	Sammensætninger til behandling af myelofibrose
DK3181128T3 (da)	2023-06-06	Farmaceutisk nilotinib-sammensætning
DK3378862T3 (da)	2022-04-11	Dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af multipel sklerose
DK2922526T3 (da)	2021-12-20	Fremstilling af semiplastiske farmaceutiske doseringsenheder
DK3116491T3 (da)	2021-08-09	Farmaceutiske sammensætninger af terapeutisk aktive forbindelser
DK3106150T3 (da)	2021-11-01	Forbedrede farmaceutiske sammensætninger af pimobendan
DK2897594T3 (da)	2020-06-29	Farmaceutisk sammensætning
DK3524260T3 (da)	2023-10-09	Farmaceutiske sammensætninger til behandling af manglende appetit
DK2939665T3 (da)	2019-06-11	Farmaceutisk sammensætning til behandling af hiv-infektioner
DK2900259T3 (da)	2020-07-13	Glycosidase-regime til behandling af infektionssygdomme
DK2892556T3 (da)	2019-08-05	Sammensætninger og fremgangsmåder til behandling af sygdomme
DK2705847T3 (da)	2014-10-06	Sammensætning til behandling af psoriasis
DK2886108T4 (da)	2023-01-30	Optimeret farmaceutisk formulering til behandling af inflammatoriske ændringer af øsofagus
DK2928454T3 (da)	2020-03-30	Triaziner til behandling af protozosygdomme
DK2828396T3 (da)	2019-05-27	Fremgangsmåde til fremstillingen af g-csf
DK2814462T3 (da)	2017-11-27	Oliebaseret farmaceutisk sammensætning til behandling af gastrointestinale sygdomme
EP2851078A4 (en)	2015-10-21	PHARMACEUTICAL COMPOSITION
BR112014021433A2 (pt)	2017-07-18	formulações farmacêuticas